Switch theme
Sign up to access all valuation multiples
Mendus AB is a clinical-level biopharmaceutical company based on the company's allogeneic dendritic cell biology focused on the development of immunotherapies that address tumor recurrence and hard-to-treat established tumors. Its operations consist of research and development for pharmaceuticals. Company Pipeline includes: Vididencel, Ilixadencel, Preclinical.
2002
28
LTM Revenue $4.2M
LTM EBITDA -$9.1M
$20.8M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Mendus has a last 12-month revenue (LTM) of $4.2M and a last 12-month EBITDA of -$9.1M.
In the most recent fiscal year, Mendus achieved revenue of n/a and an EBITDA of -$12.4M.
Mendus expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Mendus valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $4.2M | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | $4.2M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$9.1M | XXX | -$12.4M | XXX | XXX | XXX |
| EBITDA Margin | -218% | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$5.8M | XXX | -$13.5M | XXX | XXX | XXX |
| EBIT Margin | -140% | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$9.3M | XXX | -$13.2M | XXX | XXX | XXX |
| Net Margin | -223% | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Mendus's stock price is SEK 5 (or $1).
Mendus has current market cap of SEK 266M (or $27.4M), and EV of SEK 201M (or $20.8M).
See Mendus trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $20.8M | $27.4M | XXX | XXX | XXX | XXX | $-0.19 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Mendus has market cap of $27.4M and EV of $20.8M.
Mendus's trades at n/a EV/Revenue multiple, and -1.7x EV/EBITDA.
Equity research analysts estimate Mendus's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Mendus has a P/E ratio of -3.0x.
See valuation multiples for Mendus and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $27.4M | XXX | $27.4M | XXX | XXX | XXX |
| EV (current) | $20.8M | XXX | $20.8M | XXX | XXX | XXX |
| EV/Revenue | 5.0x | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -2.3x | XXX | -1.7x | XXX | XXX | XXX |
| EV/EBIT | -3.6x | XXX | -1.5x | XXX | XXX | XXX |
| EV/Gross Profit | 5.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | -3.0x | XXX | -2.1x | XXX | XXX | XXX |
| EV/FCF | -11.0x | XXX | -2.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialMendus's last 12 month revenue growth is 51%
Mendus's revenue per employee in the last FY averaged n/a, while opex per employee averaged $0.5M for the same period.
Mendus's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Mendus's rule of X is -91% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Mendus and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 51% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -218% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | -254% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -91% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Mendus acquired XXX companies to date.
Last acquisition by Mendus was XXXXXXXX, XXXXX XXXXX XXXXXX . Mendus acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Mendus founded? | Mendus was founded in 2002. |
| Where is Mendus headquartered? | Mendus is headquartered in Sweden. |
| How many employees does Mendus have? | As of today, Mendus has 28 employees. |
| Who is the CEO of Mendus? | Mendus's CEO is Dr. Erik Manting, PhD. |
| Is Mendus publicy listed? | Yes, Mendus is a public company listed on STO. |
| What is the stock symbol of Mendus? | Mendus trades under IMMU ticker. |
| When did Mendus go public? | Mendus went public in 2013. |
| Who are competitors of Mendus? | Similar companies to Mendus include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Mendus? | Mendus's current market cap is $27.4M |
| What is the current revenue of Mendus? | Mendus's last 12 months revenue is $4.2M. |
| What is the current revenue growth of Mendus? | Mendus revenue growth (NTM/LTM) is 51%. |
| What is the current EV/Revenue multiple of Mendus? | Current revenue multiple of Mendus is 5.0x. |
| Is Mendus profitable? | Yes, Mendus is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Mendus? | Mendus's last 12 months EBITDA is -$9.1M. |
| What is Mendus's EBITDA margin? | Mendus's last 12 months EBITDA margin is -218%. |
| What is the current EV/EBITDA multiple of Mendus? | Current EBITDA multiple of Mendus is -2.3x. |
| What is the current FCF of Mendus? | Mendus's last 12 months FCF is -$1.9M. |
| What is Mendus's FCF margin? | Mendus's last 12 months FCF margin is -45%. |
| What is the current EV/FCF multiple of Mendus? | Current FCF multiple of Mendus is -11.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
